

DIASORIN LAUNCHES ON ITS LIAISON XL PLATFORM THE NEW TEST FOR DETECTION OF THE IgG ANTIBODIES TO TRYPANOSOMA CRUZI WHICH CAUSES CHAGAS, FOR THE MARKET OUTSIDE THE US AND CANADA

October 10, 2013 - Saluggia (VC) - **DiaSorin** (FTSE MIB:DIA) is pleased to announce the introduction of the new **LIAISON XL Chagas test** for the qualitative detection of the antibodies to *Trypanosoma cruzi* (*T.cruzi*) in human serum and plasma for the market **outside the US and Canada only**.

Chagas disease, or American trypanosomiasis, is an infectious disease transmitted by the **Triatomine bug** when it deposits its feces on the host's skin surface and subsequently bites it.

However **the disease can also be transmitted through blood donations, organ transplants or mother to child**.

The effect of Chagas infection has an **initial acute phase** that lasts two months after transmission, and in which, in most cases, symptoms are absent or mild. Nonetheless **up to 30% of patients will develop heart damage and up to 10% will develop damage to their esophagus, colon or autonomic nervous system**.

In the late **chronic phase** of the disease, **patients** will develop all of these damages and **will ultimately die**.

The **Chagas disease is endemic in Central and Latin American countries**, growing also in non-endemic countries through migration of people and, becoming nowadays, an emerging health problem **worldwide**.

As for the **market**, according to last estimates there are around **18 million people** worldwide affected by this chronic, systemic, parasitic infection, of which about 8 million people are resident in Latin America.

In terms of value, the **current market** is estimated **around 9 million Euros, excluding the United States, Canada and Japan**.

This new test on the LIAISON XL platform is an addition to the **extensive infectious disease menu** which now reaches **45 tests** and represents a further increasing of the menu for the blood banks' market.

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	Chagas		
Diagnosis	screening the presence of antibodies to <i>Trypanosoma cruzi</i> (Chagas disease)		
Business segment	Immunodiagnosics	✓	Molecular Diagnostics
Potential market	~€ 9 mln ex USA, Canada, Japan		
Technology	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		HLA Typing
Clinical Area	Infectious Disease	✓	Infectious Disease
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		
	Bone & Mineral		Onco-hematology
	Cardiac Markers		
	GI Stool Testing		

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: *“I am proud to announce the launch of the new Chagas test which is the first step to avoid easy transmission of the disease, given the fact that most patients are chronic. By an early diagnosis of Chagas with our test on the LIAISON XL, physicians can diagnose the disease at an early stage and, consequently, prescribe the correct treatment to the affected patients and avoid transmission. Furthermore the launch of the new LIAISON XL Chagas test confirms our strong commitment to the infectious disease menu expansion, adding the 45th test in this clinical area”*.

About DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
 External Relations Director - Head of IR and Media
 Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
 Investor Relations Specialist
 Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it